The global plasma fractionation market size reached US$ 25.1 Billion in 2023. Looking forward, the market is projected to reach US$ 39.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.23% during 2023-2032.
Plasma fractionation refers to the downstream processing of donated plasma into life-saving therapies and medicinal products. It breaks plasma into individual proteins or plasma fractions using mechanical separation methods, such as centrifugation, depth filtration, precipitation, and chromatography. Nowadays, several modern fractionation processes use alcohol concentrations, time, temperature, and pH to extract specific therapeutic proteins. Moreover, increasing technology complexity over the years and the introduction of in-process viral reduction treatments have resulted in the development of new protein therapeutics and improvement in product purity and quality.
Apart from this, market players are financing research and development (R&D) activities to launch advancement in plasma production technology to improve product efficacy and enhance recovery of immunoglobulin G (IgG) to isolate new plasma proteins. Furthermore, they are focusing on developing affordable viral inactivation and processing technologies that allow utilization of local plasma resources safely. This, in confluence with the escalating need to improve yield, maintain process economics, and manage increasing regulatory requirements, is anticipated to provide a favorable market outlook in the coming years.
2. What is the expected growth rate of the global plasma fractionation market during 2024-2032?
3. What has been the impact of COVID-19 on the global plasma fractionation market?
4. What are the key factors driving the global plasma fractionation market?
5. What is the breakup of the global plasma fractionation market based on the product?
6. What is the breakup of the global plasma fractionation market based on the sector?
7. What is the breakup of the global plasma fractionation market based on the application?
8. What is the breakup of the global plasma fractionation market based on the end user?
9. What are the key regions in the global plasma fractionation market?
10. Who are the key players/companies in the global plasma fractionation market?
Plasma fractionation refers to the downstream processing of donated plasma into life-saving therapies and medicinal products. It breaks plasma into individual proteins or plasma fractions using mechanical separation methods, such as centrifugation, depth filtration, precipitation, and chromatography. Nowadays, several modern fractionation processes use alcohol concentrations, time, temperature, and pH to extract specific therapeutic proteins. Moreover, increasing technology complexity over the years and the introduction of in-process viral reduction treatments have resulted in the development of new protein therapeutics and improvement in product purity and quality.
Plasma Fractionation Market Trends
Protein products fractionated from human plasma are an essential class of therapeutics widely used to prevent, manage, and treat life-threatening conditions, such as infections, congenital deficiencies, rare blood disorders, immunologic disorders, and autoimmune disorders. A significant rise in the prevalence of these conditions among a significant part of the population globally represents one of the key factors impelling the market growth. In addition, manufacturers are developing plasma fractionation with additional safety features due to the implementation of stringent regulations and standard controls and settings by governing agencies of numerous countries on quality assurance of biological products.Apart from this, market players are financing research and development (R&D) activities to launch advancement in plasma production technology to improve product efficacy and enhance recovery of immunoglobulin G (IgG) to isolate new plasma proteins. Furthermore, they are focusing on developing affordable viral inactivation and processing technologies that allow utilization of local plasma resources safely. This, in confluence with the escalating need to improve yield, maintain process economics, and manage increasing regulatory requirements, is anticipated to provide a favorable market outlook in the coming years.
Key Market Segmentation
This report provides an analysis of the key trends in each sub-segment of the global plasma fractionation market report, along with forecasts at the global, regional and country level from 2024-2032. The report has categorized the market based on product, sector, application and end user.Breakup by Product:
- Immunoglobulins
- Albumin
- Coagulation factor VIII
- Coagulation factor IX
Breakup by Sector:
- Private Sector
- Public Sector
Breakup by Application:
- Neurology
- Immunology
- Hematology
- Other Applications
Breakup by End User:
- Hospitals and Clinics
- Clinical Research Laboratories
- Academic Institutes
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players being ADMA Biologics, Bio Products Laboratory Ltd., Boccard, Grifols, S.A., Hemarus Therapeutics Limited, Intas Pharmaceuticals Limited, LFB S.A., Merck Group, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., SK Plasma Co. Ltd. and Virchow Biotech Private Limited.Key Questions Answered in This Report
1. What was the size of the global plasma fractionation market in 2023?2. What is the expected growth rate of the global plasma fractionation market during 2024-2032?
3. What has been the impact of COVID-19 on the global plasma fractionation market?
4. What are the key factors driving the global plasma fractionation market?
5. What is the breakup of the global plasma fractionation market based on the product?
6. What is the breakup of the global plasma fractionation market based on the sector?
7. What is the breakup of the global plasma fractionation market based on the application?
8. What is the breakup of the global plasma fractionation market based on the end user?
9. What are the key regions in the global plasma fractionation market?
10. Who are the key players/companies in the global plasma fractionation market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Plasma Fractionation Market
6 Market Breakup by Product
7 Market Breakup by Sector
8 Market Breakup by Application
9 Market Breakup by End User
10 Market Breakup by Region
11 SWOT Analysis
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- ADMA Biologics
- Bio Products Laboratory Ltd.
- Boccard
- Grifols S.A.
- Hemarus Therapeutics Limited
- Intas Pharmaceuticals Limited
- LFB S.A.
- Merck Group
- Octapharma AG
- PlasmaGen BioSciences Pvt. Ltd.
- SK Plasma Co. Ltd.
- Virchow Biotech Private Limited
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 137 |
Published | April 2024 |
Forecast Period | 2023 - 2032 |
Estimated Market Value ( USD | $ 25.1 Billion |
Forecasted Market Value ( USD | $ 39.7 Billion |
Compound Annual Growth Rate | 5.2% |
Regions Covered | Global |
No. of Companies Mentioned | 12 |